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A B S T R A C T
Both colonoscopy and fecal occult blood test (FOBT) are commonly used for colorectal cancer (CRC) screening,
but colonoscopy costs much more than FOBT. Swiss insurance offers high or low deductibles and choice of basic
or private insurance. We hypothesized that high deductibles and basic insurance discourage colonoscopy, but do
not change FOBT rates.
We determined the proportion of patients tested for CRC in Switzerland (colonoscopy within 10 years, FOBT
within 2 years), and determined associations with health insurance type.
We extracted data on 50–75-year-olds from the Swiss Health Interview Surveys of 2012 to determine colo-
noscopy and FOBT testing rates (n = 7335). Multivariate logistic regression models estimated prevalence ratios
(PRs) of CRC testing associated with health insurance type (deductible and private insurance), adjusted for socio-
demographic factors (age, gender, education, income) and self-rated health.
The weighted proportion of individuals tested for CRC within recommended intervals was 39.5%. Testing
with colonoscopy was significantly associated with private insurance (PR 1.85, 95% CI: 1.46–2.35) and low
deductible (PR 2.00, 95% CI: 1.56–2.57). Testing with FOBT was significantly associated with deductible (PR
1.71, 95%CI:1.09–2.68) but not with private insurance.
About 60% of the Swiss population was not current with CRC testing. After adjusting for covariates, private
insurance and low deductible was significantly associated with higher prevalence of CRC testing, indicating that
waiving the deductible could increase CRC screening uptake and reduce health inequality.
1. Introduction
Colorectal cancer (CRC) is the third leading cause of cancer mor-
tality in Switzerland, killing 1600 people annually (Arndt et al., 2016).
Most of these lives could be saved by CRC screening (Brenner et al.,
2014; Meester et al., 2015). The US Preventive Task Force (Bibbins-
Domingo et al., 2016) and the European panel (Arditi et al., 2009)
recommend screening for patients 50–75 years old with either colo-
noscopy every ten years or faecal occult blood test (FOBT) every
1–2 years. There are few studies investigating CRC screening in Swit-
zerland, but existing studies find screening has been underused. Of
patients who visited Swiss university primary care practices in 2005
and 2006, only 33.6% were tested at recommended intervals (Fischer
et al., 2013). CRC testing rates are higher in the US, where, by 2015,
63% of the population had been tested (Schroy et al., 1997). A later
study based on the Swiss Health Interview Survey (SHIS) reported
screening rates among 50–75-year-olds were 18.9% in 2007 and 22.2%
in 2012 (Fedewa et al., 2015). However, this study solely included tests
performed for screening reasons. Diagnostic CRC testing may have a
preventive effect, so both diagnostic testing and screening should be
included in attempts to identify the eligible population never tested for
CRC (Stock et al., 2011). In Switzerland, insurance only covered diag-
nostic tests for symptomatic patients before 2013, and not screening. In
this period Switzerland lacked CRC screening programs that covered
https://doi.org/10.1016/j.pmedr.2020.101111
Received 18 March 2019; Received in revised form 18 February 2020; Accepted 26 April 2020
⁎ Corresponding author at: Institute of Primary Health Care (BIHAM), University of Bern, Mittelstrasse 43, CH-3012 Bern, Switzerland.
E-mail address: Reto.Auer@biham.unibe.ch (R. Auer).
Preventive Medicine Reports 19 (2020) 101111
Available online 04 May 2020
2211-3355/ © 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
the whole cost so, before 2013, physicians or respondents may have had
incentive to misreport the reason for CRC testing. Testing the impact of
the change in this policy will not be possible until 2019, when the 2017
SIHS survey results become available. The goal of this study is to es-
tablish the baseline relationship between screening and insurance
coverage before the 2013 change.
CRC testing rates have been associated with insurance type, a
modifiable factor in use of effective preventive care (Hsia et al., 2000;
Matthews et al., 2005; Weiss et al., 2013). High deductibles may be
associated with lower CRC testing rates, especially for colonoscopy. The
US Affordable Care Act (ACA) eliminated cost sharing for preventive
screening in 2010 and though some studies found that eliminating costs
did not change overall screening rates for colonoscopy (Mehta et al.,
2015), others found that no-charge screening raised colonoscopy rates
more among those with high-deductible health plans (HDHPs)
(≥$1000) than among those with low-deductible health plans (≤$500)
(Wharam et al., 2016). This trajectory may also be visible in Switzer-
land, where deductibles may impose financial barriers that reduce
testing rates, especially for colonoscopy, which is much more expensive
than FOBT. Insurance type is less likely to affect FOBT rates. The po-
pulation in Switzerland with cheaper insurance plans and high deduc-
tibles might be lower in their colonoscopy rate.
Some patients in Switzerland can opt for semi-private or private
insurance to cover hospital services beyond those mandated by statu-
tory health insurance such as free choice of hospital doctor or better
hospital accommodations (Biller-Andorno and Zeltner, 2015). Before
2013, some supplementary insurance packages covered CRC screening,
but researchers have not tested the association between type of in-
surance and CRC testing or adjusted for other factors associated with
type of insurance, like healthcare utilisation and income.
We thus determined the proportion of respondents tested for CRC in
Switzerland with colonoscopy within ten years or FOBT within two
years, and identified associations between testing and health insurance
type by reanalysing data from the SHIS from 2012. We explored dif-
ferential associations between self-reported reasons for CRC testing,
including screening and diagnostic CRC, and insurance type.
2. Methods
2.1. Data source
Since 1992, and every five years thereafter, the Swiss Federal
Statistics Office (SFSO) has conducted the cross-sectional, nationwide,
population-based Swiss Health Interview Survey (SHIS). The SHIS
sample represents the Swiss resident German-, French-, and Italian-
speaking population, aged 15 years and older, who live in private
households. The survey comprises a telephone interview (Part One) and
an online or hard copy postal survey (Part Two). SFSO invites all par-
ticipants to take both surveys; we included only those who had com-
pleted both.
The 2012 survey used the SFSO’s population register-based in-
dividual sampling frame (Swiss Federal Statistics Office (SFSO), 2013),
and stratified random sampling by canton and weighted each ob-
servation by region, household size, age, sex, and nationality. SFSO’s
weights assured data represented the Swiss resident population. The
SFSO collected, anonymized and shared data according to the Swiss
Federal Statistics Act (The Federal Council, 1993), so our study did not
require ethical approval given that it fell outside of the scope of the
Swiss Human Research Act.
2.2. Study variables
Our outcome of interest was type of CRC test: an FOBT only within
the last two years or a colonoscopy (with or without FOBT) within the
last ten years. We derived our outcomes from two survey questions
(originally in German, Italian and French): 1) “Have you ever had a
faecal occult blood test (FOBT)?” 2) “Have you ever had a lower gas-
trointestinal endoscopy?” Each question was followed up with 3) “What
was the reason for your last examination?” (screening, diagnostics,
clinical follow-up) and, 4) “What was the date of your last examina-
tion?” If the respondent could not supply the month and year, they were
asked, 5) “Were you examined within the last year?” The survey did not
ask respondents to distinguish between FOBTs (haemoccult [guaiac-
based] and faecal immunochemical [FIT]) tests.
To derive our co-variates, we extracted SHIS survey data on socio-
economic and health type, health-related behaviour, and healthcare
use. We chose the covariates of interest based on 1) face validity, 2) a
review of the literature on determinants of CRC testing and 3) a pre-
defined directed acyclic graph (DAG) (Supplementary File 1). We ex-
tracted information on type of insurance and deductible from answers
to 1) “What is your health insurance coverage for a hospital stay?”
(basic, semi-private, and private) and 2) “How high is your annual
deductible?” (300 CHF; 500, 1000 or 1500 CHF; 2000 or 2500 CHF). To
assess self-rating of health we extracted answers to “What is your
general health status?” (very good; good; moderate; bad; very bad). We
determined household income from the question, “How high is your
total monthly net income, minus social security taxes and pension
contributions,” based on SFSO quartiles (< 2521; 2521–3599;
3600–5199;> 5200 CHF). We used the SFSO assessment of education
to determine level of education, grouped into three categories (primary,
secondary, tertiary) that correspond to the international standard
classification of education (UNESCO, 2012). We also considered sex,
age (50–59; 60–69; 70–75), and nationality (Swiss or foreign).
2.3. Statistical analysis
Descriptive statistics indicated proportions of the population tested
by FOBT within the last two years, colonoscopy within the last ten
years, and combination of tests. Our analysis accounted for SFSO
weights. We used the Wald test to calculate p-values for differences in
testing methods between the two survey years. We described char-
acteristics of the study population, categorized by year and covariates.
We calculated percentages to describe the characteristics of responders
and the proportions of people tested with FOBT only or colonoscopy
(with and without FOBT) by survey year. We used the Chi-square test to
evaluate the association between categorical variables. In each survey
year, we used the multivariate multinomial logistic regression model to
analyse the association between CRC testing and health insurance type.
Prior to testing our study hypotheses on the association between non-
modifiable factors and modifiable factors on CRC testing in the dataset,
we draw a directed acyclic graph on the hypothesized associations (see
Supplemental File 1). We adjusted models for all covariates. We esti-
mated the prevalence ratio (PR) of each type of CRC testing and, with
95% confidence interval (CI), and compared multivariate multinomial
logistic regression models. “No testing” was the baseline category in our
model. We computed the marginal proportion of having been tested
with either FOBT only or colonoscopy (with and without FOBT) at each
level of type of insurance and deductible. We further tested if self-re-
ported “screening” or “diagnostic” CRC tests altered the measures of
association between CRC testing and the covariates in analyses strati-
fied by type of test (colonoscopy vs. FOBT). Since participants may have
changed deductible between the time they were tested for CRC and the
time they were surveyed, we tested the sensitivity of our results to self-
reported changes in insurance status. The SHIS did contain data on
participants who reported they had changed deductible within the last
12 months, and we excluded them from the main analyses to see if that
changed our outcome. Second, we restricted the outcome to colo-
noscopies performed within the last 12 months (Hamman and Kapinos,
2016). The threshold for statistical significance for all analyses was
p < 0.05. We performed all analyses with Stata version 14 (Stata Corp,
College Station, Texas, US).
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3. Results
Of the 41,008 people selected to participate in the SHIS 2012,
18,357 completed both parts of the survey. We analysed data from
7342 50–75-year old participants. From these, we excluded 7 re-
spondents for missing data on FOBT or colonoscopy (N = 7335).
Table 1 shows weighted characteristics of respondents’ co-variates.
Most respondents had the lowest deductible (48.3%) and few re-
spondents had the highest deductible (2000–2500 CHF; 14.2%). Most
participants had basic insurance (65.5%) rather than private insurance
(10.0%).
The weighted proportion of individuals tested for CRC within re-
commended intervals was 39.5% in 2012 (p < 0.001). 32.8% of in-
dividuals were tested with colonoscopy and 13.2% with FOBT (see
Fig. 1). The unadjusted prevalence of FOBT and colonoscopy vary by
nearly all covariates, except for nationality (see Supplemental File 2).
Type of insurance and deductible were associated with colonoscopy but
not with FOBT (type of insurance p = 0.79, deductible p = 0.53).
Information on all covariates was available for 5869 respondents.
Number of participants with missing values on covariates were 1199 for
income, 1121 for deductible, 430 for insurance type, 103 for physician
visits, 24 for education, 13 for self-rated status and 2 for education.
These respondents were all included in our multivariate multinomial
logistic regression models (see Supplemental File 3). Having the lowest
deductible was significantly associated with Colonoscopy (PR 2.00,
95% CI: 1.56–2.57) and FOBT (PR 1.71, 95% CI: 1.09–2.68).
Colonoscopy and private insurance were significantly associated (PR
1.85 95% CI:1.46 to 2.35); FOBT testing and private insurance were not
(PR 1.12, 95% CI: 0.84–1.49). (see Supplemental File 3). Sex and age
did not interact with type of insurance or deductible for either test (all
P > 0.10) (see Fig. 2).
Fig. 3 illustrates the marginal proportion of having either test at
each category type of insurance and level of deductible. A 60-year-old
man with private insurance and the lowest deductible had a 28 per-
centage points greater probability of having been tested for CRC than a
60-year old man with basic insurance and the highest deductible (60%
vs. 32%).
We used exploratory multinomial regression models that adjusted
for the same covariates to classify respondents into screening and di-
agnostic FOBT and colonoscopy for the results of the 2012 Survey
(Supplementary File 4). Type of insurance and deductible was asso-
ciated with both screening and diagnostic colonoscopies. Screening
FOBT was associated with deductible but not with private insurance.
Diagnostic FOBT and was not associated with deductible or private
insurance.
In total, 478/7342 (6.5%) reported changing their deductible in the
last year. In sensitivity analyses, the point estimate of the measure of
association between colonoscopy and semi-private insurance was 1.62
(95% CI: 1.31–1.91) when we excluded participants who changed their
insurance status and 2.05 (95% CI: 1.58–2.68) when we compared the
lowest to the highest deductible (Supplementary File 5).
When we restricted our analysis to colonoscopies performed within
the year, the measure of association between colonoscopy and private
insurance was 1.50 (95% CI: 1.06–2.11) and 1.76 (95% CI: 1.15–2.69)
when we compared lowest to highest deductible (Supplementary File
6).
4. Discussion
Among the Swiss population, we found 40% of 50–75-year-olds had
been tested for CRC. Colonoscopy, an expensive test, was significantly
associated with private insurance and low deductible after multivariate
adjustment for predictors of CRC testing (PR 1.88, 95% CI: 1.43–2.47).
The cheaper FOBT was not significantly associated with insurance type
but with deductible (PR 1.71, 95% CI: 1.09–2.68). In absolute terms, a
60-year-old Swiss man with private insurance and the lowest deductible
had a 28 percentage points higher chance of having been tested for CRC
than a 60-year-old man with basic insurance and the highest deductible
(60% vs. 32%).
Among the Swiss population of 50- to 75-year-olds, we found 33%
Table 1
Characteristics of 50–75-year old respondents by survey
year, from the Swiss Health Interview Survey 2012
(N = 7335).
N = 7335
%
Age (years)
50–59 45.5
60–69 38.3
70–75 16.2
Sex
Male 49.2
Female 50.8
Nationality
Swiss 84.2
Not Swiss 15.8
Education
Primary 16.4
Secondary 54.3
Tertiary 29.3
Income1
<2521 CHF2 15.5
2521–3599 CHF 22.4
3600–5199 CHF 31.4
>5200 CHF 30.7
Self-rated health
Very good 30.3
Good 46.3
Moderate 18.4
Bad 4.1
Very bad 0.9
Deductible
300 CHF 48.3
500/1000/1500 CHF 37.5
2000/2500 CHF 14.2
Insurance
Basic 65.5
Semi-private 24.4
Private 10.0
Note: Missing values: education = 24, income = 972, self-
rated health status = 10, deductible = 416,
Insurance = 229.
1Monthly household Income.
2In October 2017, 1 CHF = 0.97 US Dollar = 0.86 EUR.
Fig. 1. Weighted proportions of 50–75-year-old respondents tested for color-
ectal cancer in the Swiss Health Interview Survey 2012.
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had been tested with colonoscopy within ten years, on the high end of
the range for testing in countries outside the U.S., but lower than in
Germany. A very early 2004/2005 Survey of Health, Aging and
Retirement in Europe (SHARE) is still the largest survey of CRC testing
in Europe (11 countries), and its findings are comparable to our find-
ings in the SIHS (Stock and Brenner, 2010). SHARE found colonoscopy
rates varied widely between countries, from 6.1% in Greece to 25.1% in
France. A 2017 meta-analysis found colonoscopy use in countries
ranged from 12% to 44% for lifetime colonoscopy, and 13–30% for
recent colonoscopy (within 5–10 years), except for Germany where
55% of the screening-eligible population reported colonoscopies within
the last 5–10 year, and the U.S., where 62% reported the same (Chen
et al., 2017). A study conducted in Germany (Stock et al., 2011) ana-
lysed claims data from 2000 to 2008, and age-standardized their report
of the percentage of individuals who had had colonoscopies within
≤10 years found 23% of men and 26% of women had been tested with
colonoscopy.
We found 13% had been tested with FOBT within the last 2 years in
Switzerland. SHARE found FOBT rates ranged from 4.1% in the
Netherlands to 61.1% in Austria. The SHARE study included colono-
scopy and FOBT tests in its questionnaire, but assessed FOBT within the
last ten years. Our study assessed FOBT within recommended intervals
(the last two years). Unfortunately, SHARE has since removed CRC
screening questions, so we cannot track changes in rates over time, or
directly compare rates in Switzerland to those in other countries after
2005. Chen et al.’s meta-analysis did not report on FOBT, but reported
of the percentage of individuals who had FOBT within the last year and
found 14% of men and 22% of women in Germany had been tested with
FOBT (Stock et al., 2011). Our results affirm the increasing trend for
colonoscopies and decreasing trend for FOBT Stock et al. also identified
(Stock et al., 2011).
Our finding that testing rates and insurance type are associated
agrees with the results of studies that suggest health insurance type is
among the most important determinants of cancer screening. Data from
the Women’s Health Initiative (WHI) showed that women who did not
have prepaid health insurance plans were less likely to be screened for
breast cancer (OR 0.30–0.67) (Hsia et al., 2000). Another U.S. study
compared insured and uninsured patients and found that insured pa-
tients were more likely to be tested within guidelines for CRC testing
(OR: 7.64) (Matthews et al., 2005). Basic insurance is mandatory in
Switzerland, so 98% of the Swiss population is insured, but far fewer
are eligible or opt for semi-private or private insurance or
Fig. 2. Adjusted prevalence ratios and 95% of confidence intervals (CI) of colorectal cancer testing by fecal occult blood testing (FOBT) within the past 2 years and
colonoscopy in the past 10 years for the population of 50–75-year-olds, from the Swiss Health Interview Survey 2012.
Fig. 3. Predicted probabilities of CRC testing by FOBT within the last 2 years or
colonoscopy within the last 10 years for a 60-year old man by type of insurance
and deductible, from the Swiss Health Interview Survey 2012.
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supplementary coverage (Biller-Andorno and Zeltner, 2015). The
choice of more expensive semi-private and private policies and sup-
plements may also be a proxy for additional financial resources.
Since testing rates and deductible were associated, we expect that
Switzerland’s new reimbursement policy of 2013 will raise overall
testing rates, and especially colonoscopy rates. When the 2012 SHIS
was conducted, Switzerland reimbursed only diagnostic FOBT and co-
lonoscopy prescribed for patients who showed CRC symptoms like ab-
dominal pain, macroscopic blood in stool, or weight loss, or for patients
with high CRC risk (personal or first-degree family history of CRC, or
inflammatory bowel diseases). Patients who opted for screening with
colonoscopy or FOBT may have had to pay out-of-pocket. Colonoscopy
is at least ten times more expensive than FOBT, and this may have
lowered the overall screening rate (Wharam et al., 2016). In July 2013,
Switzerland began reimbursing colonoscopy screening every ten years
or FOBT every two years for 50–69-year-olds, but we will not know if
the new policy raised the number of people screened for CRC in the
general population until the 2017 SIHS survey results become available
in 2019. But even after the policy change, Swiss citizens must pay for
CRC tests if they have not met their deductible, unless they participate
in an organized, quality-assured program approved by the FOPH, in
which deductibles have been waived for 50–69-year-olds since 2013.
Various cantons in Switzerland will be launching such organised
screening programs over the next years. By the end of the decade, we
should be able to see if waiving the deductible lowers barriers for those
with high deductible plans and mandatory basic insurance and if
waiving the deductible raises overall CRC testing rates in Switzerland or
changes the ratio of colonoscopy to FOBT tests.
Future studies should contain budget impact analyses (BIA) of the
effects of organized screening programs on overall healthcare costs.
Several cost-effectiveness studies contrasted the incremental cost-ef-
fectiveness ratio (ICER) of colonoscopy to that of FOBT, but came to
different conclusions about the most cost-effective option over the long
term (Lansdorp-Vogelaar et al., 2011). Their models were based on
different assumptions about costs and benefits, varied in their time
horizon, and in payer perspective. Most found that CRC screening saved
between 2000 and 20,000 USD/life-year (range: cost-saving to 37,000
USD/life-years gained), falling into the commonly accepted range for
cost-effective interventions (Lansdorp-Vogelaar et al., 2011). If our
hypothesis that high deductible reduces the colonoscopy rate is true,
eliminating the deductible for CRC screening will increase healthcare
costs overall, but will be associated with better health outcomes. More
important, eliminating the deductible for colonoscopy and FOBT would
reduce the effect of out-of-pocket costs on the testing decisions of those
invited for CRC screening, and increase the likelihood they will choose
the screening option that best fits their preferences and values.
The Swiss healthcare system has some unique features that might
affect CRC testing rates. Public and private hospital physicians, and self-
employed specialists can schedule appointments in hospitals for semi-
private or private patients and be paid extra for seeing them.
Gastroenterologists are also paid extra for colonoscopies they perform
in a hospital setting for these patients, which might provide incentive to
perform more colonoscopies in this population.
4.1. Study limitations and strengths
Our study was strengthened by extensive data validation, control for
non-response, and the SFSO’s complex weighting procedure, which
ensured our sample represented the Swiss resident population.
Adjusting for carefully selected, pre-specified determinants that reflect
socio-economic, health care utilisation and health- and risk-related
factors enabled us to highlight the association between insurance status
and CRC testing. We were supported by good data collected via tele-
phone interviews, but survey data may overestimate screening rates
(Schneider et al., 2008). Though SHIS did not differentiate between
sigmoidoscopy and colonoscopy (recommended screening intervals for
the two methods differ), this may have had little effect because sig-
moidoscopy is rare in Switzerland (Marbet et al., 2008). We also had to
exclude some respondents from our adjusted model because they were
missing co-variates, mainly for income or deductible, which might in-
duce some selection bias. However, the proportion excluded was small,
limiting the importance of this bias.
The SHIS asked participants their insurance status when they were
surveyed, but did not ask what it was when they were tested. The data
available did not allow us to assess the proportion of participants who
changed deductible within the last 10 years. The SHIS did ask partici-
pants if they changed their deductible in the last year: in 2012, 6.5%
did. This rate aligns with findings from a study in Switzerland based on
administrative data from a health insurance. It estimated that, each
year, 4.5% of the insured population changes their deductible (Gerfin
et al., 2015). When we restricted our analyses to colonoscopies within
the year (when the deductible participants who underwent colonoscopy
could be expected to be same as it was when they were surveyed) the
point estimate of the association between colonoscopy and insurance
status was similar to that of the main analyses. Confidence intervals
were wider because the number of reported colonoscopies was lower in
the last 12 months than in the last 10 years.
In future, researchers should seek to analyze administrative data
from health insurers, since insurers track deductibles on an individual
level and over time.
We need to know if implementing organized screening programs in
Switzerland reduced differences associated with insurance status, and
differences in colonoscopy or FOBT rate by type of insurance, and we
will test this after 2017 SHIS data becomes available. We also look
forward to the release of data from another large survey, the European
Health Interview Survey (EHIS), which included a question about co-
lonoscopy in its 2013/2015 survey. Until this data is released we cannot
determine if the trend we identified in Switzerland is consistent with
trends in other European nations, or in Europe overall.
4.2. Conclusion
In 2012, about 60% of the Swiss population was not current with
CRC testing. After adjusting for covariates, private insurance and low
deductible were significantly associated with higher prevalence of CRC
testing, indicating that waiving the deductible could increase CRC
screening uptake and reduce health inequality.
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